Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
RNTX'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Rein Therapeutics Inc'in en son EPS'si $-1.09 olup, $-0.21 beklentilerini vurmak.
Rein Therapeutics Inc RNTX'ün son çeyrekteki geliri nasıl performans gösterdi?
Rein Therapeutics Inc'in son çeyrek geliri $-1.09
Rein Therapeutics Inc'in gelir tahmini nedir?
3 Wall Street analistine göre, Rein Therapeutics Inc'in gelir tahmini $0.0 ile $0.0 arasında değişmektedir.
Rein Therapeutics Inc'in kazanç kalite puanı nedir?
Rein Therapeutics Inc'in kazanç kalite puanı B+/46.056175'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
Rein Therapeutics Inc kazançlarını ne zaman rapor eder?
Rein Therapeutics Inc'in bir sonraki kazanç raporu 2026-06-24'te bekleniyor
Rein Therapeutics Inc'in beklenen kazançları nelerdir?
Wall Street analistlerine göre Rein Therapeutics Inc'in beklenen kazançları $0.0'dir.
Rein Therapeutics Inc kazanç beklentilerini aştı mı?
Rein Therapeutics Inc'in son kazançları $0.0 olup, beklentileri kazanmaz.